NCT04698330
Effects Of Berberine Plus Inulin On Diabetes Care in Patients With LADA
Not Yet Recruiting · Phase 4 · Second Xiangya Hospital of Central South University · registry updated 2022-02-25
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The primary purpose of this study is to evaluate the effects of oral berberine (BBR) and inulin combined with insulin therapy on diabetes care in patients with LADA.
Inclusion
- Diabetes diagnosed according to the report of WHO in 1999；
- Meet the Chinese Diabetes Society diagnostic criteria (2012) for LADA: (1)glutamic acid decarboxylase antibody (GADA) positive; (2) age at diagnosis ≧ 18 years old; (3) independent on insulin for more than 6 months after diagnosis;
- Aged between 18 and 70 years old;
- %≤HbA1c ≤10.0%;
- BMI ≥ 18.5 kg/m2, and no more than 37.5 kg/m2;
- Written informed consent from the patient or family representative.
Exclusion
- Severe liver dysfunction (ALT and AST greater than 3 times the upper limit of detection);
- eGFR \< 50ml/(min • 1.73 m2);
- Evidence of acute or chronic infection affecting glycemic control within 4 weeks prior to the first visit;
- History of any malignancy;
- Pregnancy, breastfeeding, or planned pregnancy during the study period;
- Secondary diabetes;